Antiverse is a Cardiff, UK-based biotech founded in 2017 that develops a generative AI platform for antibody drug discovery. Its computational platform designs therapeutic antibodies against challenging and historically undruggable targets, including GPCRs and ion channels, where conventional discovery struggles. By combining machine learning models with in-house experimental data generation, Antiverse predicts and designs antibody candidates to compress discovery timelines. The company has announced a research agreement with the Cystic Fibrosis Foundation to apply its platform to undruggable disease targets. Antiverse has raised across multiple rounds, including a 4.2M euro seed extension in October 2024 led by i&i Biotech Fund and Kadmos Capital, bringing total equity financing to roughly 8.6M euros, and later a $9.3M Series A led by Soulmates Ventures.